iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally.
The last earnings update was 64 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
iBio. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
iBio's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as iBio has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare iBio's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare iBio's earnings growth to the Germany market average as no estimate data is available.
Unable to compare iBio's revenue growth to the Germany market average as no estimate data is available.
Unable to determine if iBio is high growth as no earnings estimate data is available.
Unable to determine if iBio is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
iBio's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Robert B. Kay serves as Managing Director of Integrated BioPharma, Inc. He serves as a Principal, Co-Owner and Chairman of Seaway Biltmore, Inc., a hotel ownership and management company. Mr. Kay serves as Executive Chairman and Chief Executive Officer of iBio, Inc. (formerly iBioPharma Inc) since August 2008. He has more than 35 years of experience in the legal, business and pharmaceutical fields. He served as the Chairman of Paxis Pharmaceuticals, Inc. since 2002 and served as its Chief Executive Officer and President. His legal career has included considerable activity in the area of Corporate and Finance Law with broad experience in counseling financial institutions such as banks and credit card companies and in structuring and accomplishing major acquisitions and disposition transactions of banks and financial institutions domestically and internationally. He started his practice of corporate law in New York City in 1966. From 1983 to 2003 he was a Founder and Senior Corporate Partner of the New York City law firm Kay Collyer & Boose LLP where he oversaw a broad-based general corporate practice which included international transactional representation of both domestic and foreign clients, mergers and acquisitions, securities, franchising/licensing, partnerships/joint ventures, software, e-commerce and other financial transactions, with particular emphasis in the banking, credit card and hotel/hospitality industries. He has served also as a Senior Advisor to multi-national corporations in the banking, credit card and financial services industries. From January 1998 to August 2001, Mr. Kay served as a General Counsel of NIA Group, LLC. From August 2001 he has served as the President of Links Insurance Services LLC. He has been a Director of iBio, Inc since August 2008. He served as a Director of Integrated Biopharma Inc. since November 2003 to November 2008. He served as a Director of Taxolog, Inc. Mr. Canarick is a Certified Public Accountant and Attorney. Mr. Kay is a graduate of Cornell University's College of Arts and Sciences where he earned a Bachelor of Arts in Economics in 1963 and of New York University Law School where he earned a Juris Doctor degree in 1966.
Robert's compensation has been consistent with company performance over the past year.
Robert's remuneration is about average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the iBio management team is over 5 years, this suggests they are a seasoned and experienced team.
Executive Chairman & CEO
Chief Financial Officer
Chief Scientific Officer
Chief Medical Officer
President of iBio CDMO
Chief Executive Officer of IBio Brazil
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the iBio board of directors is about average.
iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company’s services cover the stages of product selection, regulatory approval, and commercial product launch. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has collaboration agreements with ONEWAY Diagnostica; AzarGen Biotechnologies (Pty) Ltd; The Texas A&M University System; and Fraunhofer Center for Molecular Biotechnology, as well as strategic relationship with CC-Pharming Ltd. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.